Drug intelligence / Profile preview

KMY

Development stage: Phase 1
Lead developer: Shanghai Leiyunshang Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

KMY is an investigational small molecule drug developed by the Lei Yunshang Group, a prominent Chinese pharmaceutical company. It is designed as a potent inhibitor of the urate transporter 1 (URAT1), a protein encoded by the SLC22A12 gene that is responsible for the reabsorption of uric acid in the renal tubules. By blocking this transporter, KMY aims to increase the renal excretion of uric acid and thereby lower serum uric acid levels in patients suffering from hyperuricemia and gout. As of early 2024, KMY is in Phase I clinical development, with studies focused on evaluating its safety, tolerability, and pharmacokinetic profile in healthy volunteers through single-ascending dose (SAD), multiple-ascending dose (MAD), and food-effect cohorts.

Other names: KMY Tablets

Targets

URAT1 (Uric Acid Transporter 1)

Beyond the preview

Go deeper on KMY.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KMY.

Explore the full profile